

Hanmi Pharmaceutical expects U.S. FDA approval for 2 new drugs

- ◆ Rolontis and Oraxol BLA/NDA approval from U.S. FDA is expected within this year
- ◆ LAPS Triple Agonist, an innovative triple-acting new drug for NASH treatment, indication expansion
- ◆ Efgpeglatide met the primary endpoint for global Phase 3
- ◆ Striving for developing rare diseases such as a once-a-month drug for short-bowel syndrome

39th Annual J.P. Morgan Healthcare Conference

Potential news flows in 2021 Hanmi

- ☑ Rolontis® The first commercial launch of a biologic with LAPS platform
- ☑ Oraxol The only oral Paclitaxel commercially available in US
- ☑ Efgpegdutide Phase2 initiation as a NASH treatment
- ☑ Efgpeglatide Regained full rights from former partner in 2020.

Will continue to development to realize its maximum value

PHASE 1	PHASE 2	PHASE 3	Registration
Belvarafenib PD-1/HER2 BsAb FLT3 inhibitor	LAPS Triple Agonist Efgpegdutide Updated LAPS Glucagon Updated LAPS GLP-2 Analog Updated Pozotinib	Efgpeglatide	Rolontis® US (1Q) Approval Oraxol US (1Q) Approval

Se Chang Kwon, the CEO of Hanmi Pharmaceutical Co., Ltd., is presenting the vision and strategy of Hanmi Pharmaceutical Co., Ltd. in 2021 at the 39th JP Morgan Conference.

◆ What will be Hanmi's 2021 R&D strategy on new drugs?

Hanmi Pharmaceutical Co., Ltd. plans to create a global R&D achievement based on innovations of inflammation ? fibrosis treatment, Triple-acting new drug for NASH (non-alcoholic steatohepatitis) treatment as well as various other innovations in metabolic disease, oncology and rare disease fields.

In particular, two new drugs developed by Hanmi Pharmaceutical Co., Ltd. are expected to be approved by the U.S. FDA this year. "Rolontis," a treatment for neutropenia that had its technology licensed out to Spectrum Pharmaceuticals, Inc. and "Oraxol," which was licensed out to Athenex, Inc. as a treatment for metastatic breast cancer, under priority review by FDA are about to announce the results of their

BLA/NDA approval (biologics license application; BLA), respectively.

“R&D capabilities of Hanmi Pharmaceutical Co., Ltd. and the strong trust among multiple partners remain solid,” stated Dr. Kwon, emphasizing “The new two drugs will be approved by FDA in the nearest future, and the expectation for Hanmi’s pipeline in this year is even greater than ever.”

◆ Indication expansion for ^{LAPS}Triple Agonist (HM15211) pre-announced

^{LAPS}Triple Agonist (HM15211), a triple agonist, has demonstrated a fatty liver reduction effect of 50% or greater through the recent clinical trials in U.S. and is being developed to be the most effective NASH treatment global wise. The fatty liver reduction effect within 12 weeks was as high as 80% compared to that of the placebo control group, and the liver enzyme lowering effect was also statistically significant.

Based on this, global Phase 2 clinical study for ^{LAPS}Triple Agonist is currently underway, and it has received Fast Track designation from FDA to expedite drug development for NASH.

U.S. FDA also designated ^{LAPS}Triple Agonist (HM15211) as an orphan drug for the treatment of primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) in 2020, and the indications will be expanded to include idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) as well.

A Phase 3 clinical study (Amplitude-M) on Efglenatide, which is being developed as a treatment for diabetes, was recently completed and met the primary endpoint by successfully achieving “30-week reduction in glycated hemoglobin(HbA1c) compared to that of placebo” in dose cohorts. The study also confirmed its weight loss effect, which was a secondary endpoint. Hanmi Pharmaceutical Co., Ltd. is planning to maximize treatment effects by combining Efglenatide with another new drugs such as ^{LAPS}Glucagon Analog(HM15136).

In addition, ^{LAPS}GLP/GCG(Efinopegdutide), which was licensed out to MSD last year, has entered the Phase 2 clinical trial this year, and the development as a NASH treatment will be accelerated.

◆ Leading the Oncology field through open innovation

Hanmi Pharmaceutical Co., Ltd. has also emphasized intensive development plans in Immuno-oncology, inflammation and fibrosis, new platforms, and rare diseases through open innovation.

Pozotinib, which succeeded in clinical trials for HER2 mutated non-small cell carcinoma (NSCLC) patients last year, is planned to be submitted to the U.S. FDA approval this year. Belvarafenib (HM95573, solid tumor), which was licensed to Genentech, Inc., is about to enter global clinical study, and a dose escalation and expansion clinical study on FLT3/SYK dual Inhibitor(HM43239), which has demonstrated complete remission in patients with FLT3 mutation acute myeloid leukemia(AML) which no existing treatments have successfully treated, is in rapid progress.

Hanmi Pharmaceutical Co., Ltd. is also pursuing T cell-targeting anti-cancer drug development substances by identifying pre-clinical substances based on AI platform technology with Standigm, Inc. In addition, the potential for the combination of oral immune anti-cancer drug candidate substance (FLX475) from RAPT Therapeutics, Inc. with Keytruda from Merck as a gastric cancer treatment is under research.

At the same time, a robust study is being conducted that involves the bispecific antibody adopted from Phanes Therapeutics, Inc. This study aims to increase the anti-cancer effect in the tumor microenvironment (TME) through synergy with Pentambody, which is also the bispecific antibody platform technology developed by Beijing Hanmi Pharm. Co., Ltd.

Furthermore, clinical study on PD-1/HER2 bispecific antibody being co-developed with Innovent Biologics, Inc. is currently underway in China to find an appropriate dose for patients with solid tumors.

◆ Striving for treatment development for rare diseases as well

Hanmi Pharmaceutical Co., Ltd. also plans to focus on its role as a pharmaceutical company for a small number of patients with rare diseases area in which has high unmet needs.

LAP^SGLP-2 Analog, which is being developed as a treatment for short bowel syndrome, that occurs in three per million, confirmed its safety and once-a-month dosing potential in the first-in-human, phase 1.

LAP^SGLP-2 Analog was also designated as an orphan drug by FDA and EMA in 2019 and was subsequently designated as a drug for rare pediatric diseases (RPDs) by FDA in 2020. It will enter a Phase 2 clinical trial this year.

In addition, the development for congenital hyperinsulinemia (CHI) and lysosomal storage disease(LSD) syndrome, are under stable progress. In particular, Phase 2 clinical trial on the treatment for congenital hyperinsulinemia was approved recently (on the 9th) by FDA, and the development is accelerating.

Se Chang Kwon, CEO of Hanmi Pharmaceutical Co., Ltd., said, "Hanmi Pharmaceutical Co., Ltd. will carry out the mission of pharmaceutical companies, which is to deliver the value for human lives, especially in this global COVID-19 pandemic. We plan to do so by proceeding the projects to cope with COVID-19 including development of diagnostics, vaccines, and treatments. In addition, we will do our best to meet the expectations towards the R&D of Hanmi Pharmaceutical Co., Ltd. by obtaining FDA approval for new drugs as well as accelerating clinical progress to increase the value of various pipelines."

Innovative R&D Pipeline (Dec 2020)



	Pre-Clinical	Phase 1	Phase 2	Phase 3 / Registration
8 Obesity/NASH Diabetes	HM14320 (LALA)Glucagon Combo Obesity/NASH/Diabetes	HM15136 (LALA)Glucagon Analog Obesity	Efinopegdutide (LALA)GLP/GCG NASH	Etpeglenatide (LALA)Exd4 Analog Diabetes
	HM14220 (LALA)Insulin Combo Diabetes	HM12460A / HM12470 (LALA)Insulin Diabetes	HM15211 (LALA)Triple Agonist NASH	
	HM12480 (LALA)Insulin148 Diabetes			Under BLA/NDA Review
12 Oncology	HM97662 (EZH1/2 Dual Inhibitor) Solid tumors / Hematology malignancies	Belvarafenib (Pan-RAF Inhibitor) Solid tumor	Pozotinib (Pan-HER Inhibitor) NSCLC & Breast cancer	Rolontis® (Elipeggrastim) Neutropenia
	BH3620 (Indisaclosed BsAb) Targeted immuno-oncology	HM43239 (FLT3 Inhibitor) AML	Oratecan (Oral Irinotecan + Encequidar) Solid tumor	Oraxol (Oral Paclitaxel + Encequidar) Metastatic Breast cancer
	BH3120 (PD-L1/4-1BB BsAb) Solid tumor	IBI315/BH2950 (PD-1/HER2 BsAb) Targeted immuno-oncology	Oradoxel (Oral Docetaxel + Encequidar) Solid tumor	
			FLX475 (CCR4 inhibitor) Gastric Cancer	
5 Rare Diseases	HM15450 (LALA)AsB Mucopolysaccharidosis	Luminat® (Integrin inhibitor) Retinitis Pigmentosa	HM15136 (LALA)Glucagon Analog Congenital hyperinsulinism	
			HM15912 (LALA)GLP-2 Analog Short bowel syndrome	
3 Others			Efpegmatropin (LALA)hGH GH deficiency	
			Luminat® (Integrin inhibitor) Diabetic Macular Edema	
			HM71224 (BTK Inhibitor) Autoimmune/Allergic diseases	
			Oraxol (Oral Paclitaxel + Encequidar) Angiosarcoma	

11

Pipeline for new drug candidates of Hanmi Pharmaceutical Co., Ltd. (PPT presentation data)